ReviewFrontiers in immunology2026
DOCK8 in immune cells: roles and mechanisms.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
DOCK8 (dedicator of cytokinesis 8) is a prominent member of the DOCK-C subfamily and functions as an atypical guanine nucleotide exchange factor (GEF). It primarily activates Rho family small GTPases-most notably Cdc42-to orchestrate cytoskeletal remodeling, and it integrates multiple key signaling pathways to preserve the functional integrity of immune cells. Recent work has established DOCK8 as a central player in both innate and adaptive immunity. In T cells, DOCK8 contributes to migration, immunological synapse assembly, lineage specification, and long-term survival, thereby supporting antiviral defense and immune homeostasis. In B cells, it fine-tunes BCR signaling, amplifies CD19-driven signals, coordinates metabolic reprogramming, and facilitates germinal center reactions, all of which underpin humoral immunity and immunological memory. In NK cells, DOCK8 influences cytotoxic activity and tissue localization by modulating immunological synapse architecture and proximal receptor signaling. In dendritic cells and macrophages, it helps regulate chemotactic migration and immune activation by precisely controlling Cdc42 activity and cytoskeletal dynamics. Mechanistically, DOCK8 serves as a signaling hub that integrates inputs from the TCR, BCR, and Toll-like receptors, coordinating the establishment of cell polarity, directed migration, immunological synapse stability, and effector function. Deficiency of DOCK8 leads to a complex immunodeficiency syndrome characterized by impaired immune surveillance, heightened susceptibility to viral, bacterial, and fungal infections, as well as allergic manifestations and disrupted immune tolerance. Although considerable progress has been made in understanding DOCK8, the integrated mechanisms operating across different immune cell types and signaling networks still await systematic elucidation. Future investigations should focus on dissecting multi-tiered signaling networks and exploring targeted interventional strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.